Semi-Synthetic 17beta-Hydroxywithanolides (17-Bhws) Promote Caspase-8-Dependent Apoptosis in Renal Carcinoma and Melanoma and Specifically Inhibit Human Prostate Cancer Cell Proliferation

Case ID:

This novel, partially naturally-derived compound can be used to treat three different kinds of cancer (melanoma, renal carcinoma, and prostate cancer) in patients without other treatment options.


The treatment of all kinds of cancers leaves much to be desired in terms of an efficient treatment that is highly effective and has comparably lower side-effects. Treatments that target multiple kinds of cancers and are precise in their targeting are in high demand. The compound in this invention has the potential to treat melanoma, renal carcinoma, and/or prostate cancer patients.



  • Melanoma, renal carcinoma and prostate cancer treatment  


  • Prevents proliferation of prostate cancer cells
  • Sensitizes melanoma and renal carcinoma to cell death
  • Provides a potential treatment for patients without other options
  • Highly efficient
  • Provides precise targeting
  • Partially naturally derived
Patent Information:
Contact For More Information:
Tod McCauley
Assistant Director of Licensing, CALS
The University of Arizona
Lead Inventor(s):
Leslie Gunatilaka
Kithsiri Wijeratne
Yaming Xu
Thomas Sayers
Poonam Tewary
Alan Brooks